This study evaluated the protective role of farnesoid-X-receptor (FXR) agonist INT-787 in the control of mitochondrial changes using a metabolic dysfunction-associated steatohepatitis (MASH) model. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.